AGREEMENTS WITH PFIZER (Narrative) (Details) - USD ($) $ in Millions	1 Months Ended		12 Months Ended
	Oct. 31, 2015	Nov. 30, 2009	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2012	Oct. 12, 2015
Revenue Recognized Over Designated Period				$ 4.6
Proceeds from Collaborators		$ 60.0
Milestone Payment	$ 25.0
Revenue Recognition, Multiple-deliverable Arrangements, Performance Period			14 years
Protalix Bio Therapeutics Incorporation [Member]
Collaborative Arrangement Profit Share Percentage	40.00%
Collaboration Operation [Member]
Accrued Liabilities						$ 4.3
Pfizer [Member]
Stock Issued During Period, Shares, New Issues	5,649,079
Debt Instrument, Face Amount	$ 4.3
Fair Value, Net Asset (Liability), Total	46.0
Equity, Fair Value Disclosure, Total	6.1
Indefinite-lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure	39.9
Upon Filing of Pediatric Investigation Plan to EMA [Member]
Proceeds from Collaborators	$ 5.0		$ 5.0
Upon FDAApproval [Member]
Milestone Payment					$ 25.0